~~<i id='D875B704D4'><strike id='D875B704D4'><tt id='D875B704D4'><pre id='D875B704D4'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-08-23 08:09:52 Page View：2817

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Just how powerful is the placebo effect?
Next article： Apple is now the first public company to be valued at $3 trillion

explore

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Copay coupons to count toward deductibles, after Biden court move

AdobeWASHINGTON—Insurerswillhavetocountdrugcopaycouponstowarddeductiblesandpatientspendingcapsinmost

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

The new shift in health care is toward less care

AdobeTheopioidcrisisrockedAmerica,bringingaddictionandoverdoseintothespotlight.Butitalsohighlightedt